Opaleye Management, Inc. has recently announced that it has increased stake in Ocular Therapeutix Inc (NASDAQ:OCUL) by 11.90%. After grabbing 6.47 million shares, the institutional investor is now in possession of 0.69 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.15% having worth around $18.43 million. Moreover, BlackRock Fund Advisors increased its share by 66727.0 to have a control over 4.81 million shares. And The Vanguard Group, Inc. raised its holdings to 10729.0 shares by acquiring 3.9 million shares or 4.92% of the stake.
Ocular Therapeutix Inc (OCUL) concluded trading on 12/14/23 at a closing price of $3.79, with 7.17 million shares of worth about $27.16 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -23.74% during that period and on Thursday the price saw a loss of about -3.81%. Currently the company’s common shares owned by public are about 77.20M shares, out of which, 75.19M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 19 times over the past 12 months. They bought 489,912 shares in 13 of the transactions. In 6 selling transactions, insiders dumped 45,403 shares.
Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Ocular Therapeutix Inc Vanguard Total Stock Market ETF is currently holding 2.31 million shares of worth totaling $6.59 million. The company recently came buying 0.0 shares which brought its stake up to 2.91% of the company’s outstanding shares. iShares Russell 2000 ETF sold 18054.0 shares, after which its hold over company’s outstanding shares shrunk to 2.27%, leaving 1.8 million shares with the mutual fund that have a worth of about $5.12 million. Vanguard Extended Market Index Fu, after buying 1.15 million shares, have now control over 1.44% of the stake in the company. It holds 0.0 shares of worth $3.27 million.
Stock saw a price change of 1.88% in past 5 days and over the past one month there was a price change of 72.27%. Year-to-date (YTD), OCUL shares are showing a performance of 34.88% which increased to 31.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.00 but also hit the highest price of $7.96 during that period. The average intraday trading volume for Ocular Therapeutix Inc shares is 912.35K. The stock is currently trading 33.75% above its 20-day simple moving average (SMA20), while that difference is up 40.59% for SMA50 and it goes to -14.67% lower than SMA200.
Opaleye Management, Inc. acquired 6.47 million shares of Ocular Therapeutix Inc having value of about $18.43 million. Data submitted at the U.S SEC by Opaleye Management, Inc. revealed that the firm now holds 0.69 million shares in the company valued at close to $2607520.0, or have control over 11.90% stake in the company. Ocular Therapeutix Inc (NASDAQ: OCUL) currently have 77.20M outstanding shares and institutions hold larger chunk of about 51.07% of that. Holding of mutual funds in the company is about 29.98% while other institutional holders and individual stake holders have control over 35.87% and 15.24% of the stake respectively.
The stock has a current market capitalization of $301.00M and its 3Y-monthly beta is at 0.94. It has posted earnings per share of -$1.11 in the same period. It has Quick Ratio of 3.96 while making debt-to-equity ratio of 10.58. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OCUL, volatility over the week remained 10.25% while standing at 10.20% over the month.
Analysts are in expectations that Ocular Therapeutix Inc (OCUL) stock would likely to be making an EPS of -$0.33 in the current quarter, while forecast for next quarter EPS is -$0.25 and it is -$1.05 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.54 which is -$0.25 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.24 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -11.96% while it is estimated to decrease by -1.94% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on April 21, 2023 offering an Outperform rating for the stock and assigned a target price of $18 to it.
